HessDR. Aerosol therapy during noninvasive ventilation or high-flow nasal cannula. Respir Care, 2015; 60(6):880-891. discussion 891-893.
2.
LiJ, TuM, YangL, JingG, FinkJB, BurtinC, et al. Worldwide clinical practice of high-flow nasal cannula and concomitant aerosol therapy in the adult ICU setting. Respir Care, 2021; 66(9):1416-1424.
3.
BeuvonC, CoudroyR, BardinJ, MarjanovicN, RaultC, BironneauV, et al. Beta agonist delivery by high-flow nasal cannula during COPD exacerbation: a prospective physiological study. Respir Care, 2022; 67(1):9-15.
4.
BraunlichJ, WirtzH. Oral versus nasal high-flow bronchodilator inhalation in chronic obstructive pulmonary disease. J Aerosol Med Pulm Drug Deliv, 2018; 31(4):248-254.
5.
CorcoranTE, SavilleA, AdamsPS, JohnstonDJ, CzachowskiMR, DomninaYA, et al. Deposition studies of aerosol delivery by nasal cannula to infants. Pediatr Pulmonol, 2019; 54(8):1319-1325.
6.
Colaianni-AlfonsoN, MacLoughlinR, EspadaA, SaaY, TecheraM, ToledoA, et al. Delivery of aerosolized bronchodilators by high-flow nasal cannula during COPD exacerbation. Respir Care, 2023; 68(6):721-726.
7.
SaundersJL, DavisMD. Transnasal aerosol delivery during high-flow nasal cannula therapy. Respir Care, 2022; 67(1):149-150.
8.
KuchBA, LinssenR, YoshikawaH, SmallwoodCD, DavisMD. Local effects of two intravenous formulations of pulmonary vasodilators on airway epithelium. Respir Care, 2020; 65(10):1427-1432.
9.
DavisMD, DonnSM, WardRM. Administration of inhaled pulmonary vasodilators to the mechanically ventilated neonatal patient. Paediatr Drugs, 2017; 19(3):183-192.
10.
MaazA, BlagbroughIS, De BankPA. In vitro evaluation of nasal aerosol depositions: an insight for direct nose to brain drug delivery. Pharmaceutics, 2021; 13(7):1079.
11.
Le GuellecS, EhrmannS, VecellioL. In vitro - in vivo correlation of intranasal drug deposition. Adv Drug Deliv Rev, 2021; 170:340-352.
12.
VyasTK, ShahiwalaA, MaratheS, MisraA. Intranasal drug delivery for brain targeting. Curr Drug Deliv, 2005; 2(2):165-175.
13.
GraffCL, PollackGM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci, 2005; 94(6):1187-1195.
14.
EspinozaLC, Silva-AbreuM, ClaresB, Rodríguez-LagunasMJ, HalbautL, CañasMA, CalpenaAC. Formulation strategies to improve nose-to-brain delivery of donepezil. Pharmaceutics, 2019; 11(2):64.
